Higher type 2 diabetes-related mortality when HbA1c levels are too low.
The Accord randomised trial compared two HbA1c target values (less than 6% versus 7.0-7.9%) in about 10 000 patients with type 2 diabetes. The trial was discontinued prematurely in 2008 because the overall mortality rate was significantly higher in the "less than 6%" group (1.4% versus 1.1% per year)
D015415:Biomarkers / Q000097:blood; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D003925:Diabetic Angiopathies / Q000097:blood / Q000517:prevention & control; D005602:France; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism / Q000592:standards*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D017410:Practice Guidelines as Topic / Q000592:standards*; D016032:Randomized Controlled Trials as Topic
D015415:Biomarkers; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents